0
Allergy and Airway |

Pooled Safety Analysis of Once-Daily Tiotropium and Olodaterol Fixed-Dose Combination via the Respimat in Patients With Chronic Obstructive Pulmonary Disease: Two 1-Year Studies

Roland Buhl; Roger Abrahams; Leif Bjermer; Eric Derom; Matjaz Flezar; Jacques Hébert; Anthony Veale; Lars Groenke; Kay Tetzlaff; Lawrence Korducki; Holger Huisman; Stella Waitere-Wijker; Lorcan McGarvey
Author and Funding Information

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany


Chest. 2014;146(4_MeetingAbstracts):48A. doi:10.1378/chest.1994476
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Treatment Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: Tiotropium, a long-acting muscarinic antagonist, has recently been assessed in fixed-dose combination (FDC) with olodaterol, a once-daily, long-acting β2-agonist, for treatment of chronic obstructive pulmonary disease (COPD). We present pooled safety data from two pivotal, replicate, Phase III studies assessing efficacy and safety of FDCs of tiotropium and olodaterol(T+O) delivered via Respimat® inhaler in patients with GOLD stage 2-4 COPD.

METHODS: In these 52-week, double-blind, parallel-group studies, patients were randomized to five arms: once-daily olodaterol 5 µg, tiotropium 2.5 µg, tiotropium 5 µg, T+O 2.5/5 µg, T+O 5/5 µg. Key inclusion criteria included: age ≥40 years, diagnosis of COPD, smoking history >10 pack-years. Patients with a history of asthma or significant disease other than COPD were excluded; however, patients with stable cardiovascular co-morbidities were included. Adverse events (AEs) were reported throughout.

RESULTS: In total, 5162 patients were randomized and treated. AEs, serious AEs, and fatal AEs were generally balanced across treatment groups. AE incidence was 76.6% (olodaterol 5 µg), 73.4% (tiotropium 2.5 µg), 73.3% (tiotropium 5 µg), 74.7% (T+O 2.5/5 µg), and 74.0% (T+O 5/5 µg). The most frequently reported AEs were respiratory events (according to MedDRA System Organ Class), including COPD exacerbations (34.1-35.6% with monotherapies versus 29.2-32.3% with FDCs) and dyspnea (3.7-4.9% with monotherapies versus 3.9-4.2% with FDCs). Frequencies of cardiac disorders were generally balanced across groups (4.5-5.8%), while respiratory events were more frequent among patients treated with monotherapies (42.7-45.3%) than FDCs (38.2-39.4%). Most events were mild to moderate in severity and not considered related to study treatment. Groups receiving T+O FDCs reported fewer rescue medication usages compared to groups receiving single components.

CONCLUSIONS: T+O FDCs were well tolerated with no increase in incidence of AEs compared to individual components.

CLINICAL IMPLICATIONS: The equivalent tolerability of T+O FDCs compared to the monotherapies suggests there are no safety signals with the combined therapy in patients with COPD. Funding: Boehringer Ingelheim. Editorial assistance: Complete HealthVizion.

DISCLOSURE: Roland Buhl: Consultant fee, speaker bureau, advisory committee, etc.: Astra Zeneca, Consultant fee, speaker bureau, advisory committee, etc.: Boehringer Ingelheim, Consultant fee, speaker bureau, advisory committee, etc.: Chiesi, Consultant fee, speaker bureau, advisory committee, etc.: Grifols, Consultant fee, speaker bureau, advisory committee, etc.: GSK, Consultant fee, speaker bureau, advisory committee, etc.: Novartis, Consultant fee, speaker bureau, advisory committee, etc.: Roche, Consultant fee, speaker bureau, advisory committee, etc.: Takeda Roger Abrahams: Grant monies (from industry related sources): Clinical Research Grant from Boehringer Ingelheim, Consultant fee, speaker bureau, advisory committee, etc.: Boehringer Ingelheim steering committe Leif Bjermer: Fiduciary position (of any organization, association, society, etc, other than ACCP: Principle Investigator, Consultant fee, speaker bureau, advisory committee, etc.: Boehringer Advisory Board Eric Derom: Consultant fee, speaker bureau, advisory committee, etc.: Consultant - Boehringer Ingelheim & Actelion, Consultant fee, speaker bureau, advisory committee, etc.: Speaker - - Boehringer Ingelheim and GSK, Consultant fee, speaker bureau, advisory committee, etc.: Advisory Board - Chiesi & Astra Zeneca Matjaz Flezar: Consultant fee, speaker bureau, advisory committee, etc.: Boehringer Ingelheim Advisory Board, Grant monies (from industry related sources): Principle Investigator in Boehringer Ingelheim Clinical Trials Jacques Hébert: Other: Board Memeber: Novartis, King (Pfizer), Palladin, Merck, CSL Behring, Other: Centre de Recherche involved with clinical trials sponsored by Boehringer Ingelheim, Merck, Novartis, Circassia CSL Behring Lars Groenke: Employee: Boehringer Ingelheim Kay Tetzlaff: Employee: Boehringer Ingelheim Lawrence Korducki: Employee: Boehringer Ingelheim Holger Huisman: Employee: Boehringer Ingelheim Stella Waitere-Wijker: Employee: Boehringer Ingelheim Lorcan McGarvey: Consultant fee, speaker bureau, advisory committee, etc.: Consultant fees for adjudication activity on COPD clinical trials The following authors have nothing to disclose: Anthony Veale

This presentation will describe the Phase III study investigating the safety and efficacy of a tiotropium plus olodaterol fixed dose combination therapy for the treatment of COPD


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543